CareDx Shares Jump 124.7% in 3 Months as AlloSure Plus, EHR Push Lift Outlook

1 articles · Updated · Yahoo Finance · Aug 23

CareDx stock climbed to $48.61 after a 30.9% one-month gain and a 124.7% three-month surge, as investors reassessed the transplant diagnostics company's growth prospects.
AlloSure Plus and integration with electronic health record systems including Epic are driving that optimism by supporting broader precision-medicine adoption, reimbursement and potential margin improvement.
A widely followed valuation view pegs fair value at $52.33, about 7.1% above the latest close, suggesting the rally may still leave modest upside.
The stock still trades at 22.7 times earnings versus 17.4 times for U.S. biotechs, leaving valuation exposed if growth expectations fade or sentiment cools.
Medicare reimbursement changes and any misstep integrating Naveris remain key risks as CareDx tries to sustain its sharp year-to-date advance.